Price
No data yet.
Social Signal Score
Analyst Ratings
18 analystsRevenue
$203.97M+173.37%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Christopher David Young
- Sector
- Technology
- Industry
- Software - Application
- Employees
- 2,000
- Beta
- 0.82
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 1.58
Financials
Revenue
$203.97M+173.4%Net Income
$9.04M+23.5%EBITDA
$-16.32M-216.3%Free Cash Flow
$10.55M+491.5%EPS (diluted)
$0.06+6.2%Shares Outstanding (diluted)
161.39M+24.5%Operating Expenses
$127.85MCash & Debt
$230.49MReturn of Capital
$26.56MRevenue by Segment (annual)
$1.39BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $748.44M | $7.21M | $0.05 |
| 2024 | $666.78M | $-52.73M | $-0.34 |
| 2023 | $572.39M | $-13.09M | $-0.09 |
| 2022 | $491.62M | $-12.30M | $-0.08 |
| 2021 | $425.55M | $-1.48M | $-0.01 |
| 2020 | $374.67M | $-75.08M | $-0.60 |
| 2019 | $321.50M | $31.06M | $0.21 |
| 2018 | $272.40M | $-6.11M | $-0.05 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.07
- Implied price
- $1.32
- Return from $12.01
- -35.7% a year
To earn 15.0% a year on these assumptions you'd need to buy at $0.66 — -94.5% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | -46.2% | -43.7% | -41.6% | -39.8% | -38.2% |
| 3.0% | -43.4% | -40.9% | -38.7% | -36.7% | -35.0% |
| 8.0% | -40.7% | -38.0% | -35.7% | -33.7% | -31.9% |
| 13.0% | -37.9% | -35.1% | -32.7% | -30.6% | -28.7% |
| 18.0% | -35.2% | -32.2% | -29.7% | -27.5% | -25.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
160+220.00%Social Signal Score
Mentions (18)
- Newsfool.com·4d ago·Positive
Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? Axsome Therapeutics is delivering explosive revenue growth as it scales its commercial portfolio for central nervous system disorders. Vertex Pharmaceuticals remains a highly profitable giant with absolute dominance in cystic fibrosis and expanding reach in gene therapy.
View source ↗ - Newsglobenewswire.com·5d ago·Neutral
Vertex Appoints DataRobot CEO Debanjan Saha to Board of Directors KING OF PRUSSIA, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), the Decision-to-Defense™ global indirect tax and compliance company, today announced the appointment of Debanjan Saha to its Board of Directors, effective October 7, 2026.
View source ↗ - Newsfool.com·7d ago·Neutral
2 Wall Street Analysts Think Vertex Pharmaceuticals Stock Can Soar Another 20% or More Over the Next 12 Months. Here's Why They're Right. Vertex Pharmaceuticals is the leader in the cystic fibrosis market and has the intellectual property to maintain this dominance. The company has expanded into additional treatment areas and is awaiting a regulatory decision for another potential new product in the coming weeks.
View source ↗ - Newszacks.com·12d ago·Negative
Vertex Posts Positive Phase II Data on Kidney Disease Drug VRTX announces positive AMPLIFIED data for inaxaplin, while completing AMPLITUDE enrollment and targeting interim results in early 2027.
View source ↗ - Newsbenzinga.com·13d ago·Negative
Vertex Touts Encouraging Data From 'Underappreciated' Kidney Drug Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Tuesday reported data from its Phase 2b AMPLIFIED trial evaluating inaxaplin in individuals with APOL1-mediated kidney disease (AMKD).
View source ↗ - Newsmarketbeat.com·22d ago·Neutral
Vertex Pharmaceuticals Eyes Renal Growth With Key PDUFA, Pipeline Catalysts Ahead Vertex Pharmaceuticals NASDAQ: VRTX is continuing to broaden its business beyond cystic fibrosis, with its renal medicine portfolio, rare endocrine assets and cell therapies among the company's priorities, CEO and President Reshma Kewalramani said at Morgan Stanley's 24th Annual Healthcare Conference.
View source ↗ - Newsmarketbeat.com·24d ago·Neutral
Vertex Pharmaceuticals Highlights Catalyst-Rich Pipeline Beyond Cystic Fibrosis Vertex Pharmaceuticals NASDAQ: VRTX highlighted a series of upcoming clinical, regulatory and commercial catalysts across renal disease, pain management, cystic fibrosis and endocrinology during a Wells Fargo healthcare conference appearance.
View source ↗ - Newsmarketbeat.com·24d ago·Neutral
Vertex Pharmaceuticals Maps Growth Beyond CF at Cantor Conference Vertex Pharmaceuticals NASDAQ: VRTX outlined a broadening commercial and clinical strategy at the Cantor Global Healthcare Conference, highlighting its recent Crinetics acquisition, planned renal product launch efforts and upcoming pipeline milestones across kidney disease, pain, cystic fibrosis and rare endocrine disorders.
View source ↗ - Newsfxempire.com·25d ago·Positive
Strong Core Business, Raised Guidance Push Vertex Pharmaceuticals Higher Since 2008, Vertex Pharmaceuticals, Inc. (VRTX) shares have received 42 outlier institutional inflow signals and gained over 1,682%.
View source ↗ - Newsseekingalpha.com·26d ago·Positive
Vertex, Inc. (VERX) Presents at Goldman Sachs Communacopia + Technology Conference 2026 Transcript Vertex, Inc. (VERX) Presents at Goldman Sachs Communacopia + Technology Conference 2026 Transcript
View source ↗ - Newsfool.com·27d ago·Positive
Goldman Sachs Just Added Vertex Pharmaceuticals to Its Conviction List. Here's the Bull Case for the Big Biotech Stock Vertex Pharmaceuticals' core business is rock-solid, but it is also slowly expanding into new areas. The company should see improved top-line growth over the next few years, driven by new launches.
View source ↗ - Newsfool.com·31d ago·Positive
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? Vertex Pharmaceuticals is slowly but surely expanding beyond its highly successful core therapeutic area. Regeneron has successfully rebounded after facing biosimilar competition for a key growth driver, and it boasts several attractive pipeline candidates.
View source ↗ - Newsglobenewswire.com·33d ago·Neutral
Vertex to Present at the Goldman Sachs Communacopia + Technology Conference KING OF PRUSSIA, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), the Decision-to-Defense™ global indirect tax and compliance company, today announced that Chris Young, President and Chief Executive Officer, and John Schwab, Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs Communacopia + Technology Conference on Wednesday, September 9, 2026 at 1:05 PM Pacific Time.
View source ↗ - Newsbusinesswire.com·40d ago·Neutral
Vertex to Participate in Upcoming September Investor Conferences BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in four upcoming investor conferences. Susie Lisa, Senior Vice President of Investor Relations and Manisha Pai, Executive Director of Investor Relations, will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 4:30 p.m. EDT. Susie Lisa and Manisha P
View source ↗ - Newszacks.com·40d ago·Negative
Vertex Pharmaceuticals Up 15% in a Month: How to Play the Stock Vertex's stock is up 15% in a month as strong CF sales, rising non-CF drug revenues and renal pipeline progress boost its growth story.
View source ↗ - Newsfool.com·45d ago·Neutral
Vertex Pharmaceuticals: A Biotech Cash Cow With Pipeline Upside? Explore the exciting world of Vertex Pharmaceuticals (VRTX +1.44%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
View source ↗ - Newsseekingalpha.com·53d ago·Neutral
Vertex Pharmaceuticals: I Was Wrong About Its Near-Term Prospects (Rating Upgrade) I was too cautious previously on Vertex Pharmaceuticals' prospects. Revenue from its cystic fibrosis franchise grew 10% quarter-on-quarter and 10.6% year-on-year to about $3.21 billion in Q2. On July 6, VRTX announced the acquisition of Crinetics Pharmaceuticals for about $10 billion, thereby strengthening its position in the endocrinology drugs market.
View source ↗ - Newsglobenewswire.com·54d ago·Neutral
Vertex Report: Rising Sales Tax Rates Signal a New Era of Tax Volatility KING OF PRUSSIA, Pa., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), the Decision-to-Defense™ global indirect tax and compliance company, today released its 2026 Mid-Year U.S. Sales Tax Rates and Rules Report, revealing that the combined average U.S. sales tax rate climbed for the first time in four years to reach a 10-year high of 10.1881%.
View source ↗
Earnings
Mon, Nov 2(in 4 weeks)
Consensus estimate $0.22 per share
Typical surprise +6.3% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 3$0.20 vs $0.19beat
- Thu, May 7$0.17 vs $0.16beat
- Wed, Feb 11$0.17 vs $0.17beat
- Mon, Nov 3$0.17 vs $0.17beat
- Wed, Aug 6$0.15 vs $0.14beat
- Wed, May 7$0.15 vs $0.13beat
Estimates and results for VERX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by VERX officers and directors.
- Bought
- $6.5m
- Sold
- $45.2m
5 trades
13 trades
- Destefano Davidsold
- Item Second Irr. Trust Fbo Kyle R. Westphal U/a Of Jeffrey R. Westphal Dated October 5, 2001bought
- Young Christopher Davidbought
- Andersen Eric C.bought
- Westphal Jeffreybought
- Westphal Jeffreybought
- Item Second Irr. Trust Fbo Anne Marie Westphal U/a Of Jeffrey R. Westphal Dated October 5, 2001sold
- Item Second Irr. Trust Fbo Anne Marie Westphal U/a Of Jeffrey R. Westphal Dated October 5, 2001sold
82 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in VERX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.